Â鶹´«Ã½

  • By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement

We only need a few more clicks to be able to show the most read stories for this topic. Take a look at the latest headlines below and help us out by clicking on what you find interesting!

Yesterday
PR Newswire (Press Release)16:03 8-Nov-24
CBC.ca12:17 8-Nov-24
Pharmacy Times12:01 8-Nov-24
HealthDay11:47 8-Nov-24
Toronto Star11:18 8-Nov-24
CTV News Calgary09:03 8-Nov-24
GlobeNewswire (Press Release)07:08 8-Nov-24
In the last 7 days
Nature.com23:56 7-Nov-24
Nature.com20:20 7-Nov-24
Business Wire (Press Release)16:02 7-Nov-24
DGAP07:01 7-Nov-24
Undark06:22 7-Nov-24
The Hindu19:11 6-Nov-24
Journal of American Medical Associations11:48 6-Nov-24
Nature.com11:14 6-Nov-24
PR Newswire (Press Release)08:30 6-Nov-24
The Scientist03:06 6-Nov-24
BioSpectrum Asia00:58 6-Nov-24
The Tribune, California04:34 5-Nov-24
Oswaldo Cruz Foundation (Press Release)02:46 5-Nov-24
TipRanks16:48 4-Nov-24
The Straits Times10:26 4-Nov-24
Zacks09:39 4-Nov-24
FiercePharma08:12 4-Nov-24
Center for Biosimilars07:17 4-Nov-24
DGAP07:08 4-Nov-24
DGAP07:08 4-Nov-24
GlobeNewswire (Press Release)06:45 4-Nov-24
The Good Men Project02:39 4-Nov-24
The Varsity15:08 3-Nov-24
Nature.com06:41 2-Nov-24
Nature.com04:56 2-Nov-24
In the last month
Massachusetts Institute of Technology17:03 1-Nov-24
pharmaphorum14:20 1-Nov-24
AsiaOne11:06 1-Nov-24
Chemistry World Magazine10:40 1-Nov-24
HumanProgress09:46 1-Nov-24
Genetic Engineering and Biotechnology News09:17 1-Nov-24
Genetic Engineering and Biotechnology News09:17 1-Nov-24
Phys.org06:24 1-Nov-24
Absolutely Maybe Blog20:07 31-Oct-24
Business Wire (Press Release)16:04 31-Oct-24
TipRanks13:47 31-Oct-24
Business Wire (Press Release)13:34 31-Oct-24
BioSpectrum Asia10:55 31-Oct-24
Business Wire (Press Release)09:05 31-Oct-24
UK BioIndustry Association (Press Release)20:20 30-Oct-24
News @ Northeastern17:13 30-Oct-24
Discover Magazine09:14 30-Oct-24
Business Wire (Press Release)05:41 30-Oct-24
Nature.com22:05 29-Oct-24
Annenberg Political Fact Check16:30 29-Oct-24
Pharmacy Times16:28 29-Oct-24
Clinical Trials Arena07:16 29-Oct-24
Benzinga12:54 28-Oct-24
DGAP08:04 28-Oct-24
Hospital Healthcare07:37 28-Oct-24
Business Wire (Press Release)06:52 28-Oct-24
Nature.com05:17 28-Oct-24
Nature.com05:17 28-Oct-24
Hospital Pharmacy Europe04:22 28-Oct-24
News-Medical.Net20:04 27-Oct-24
Nature.com15:08 27-Oct-24
Scrip Pharma Intelligence01:50 26-Oct-24
NBC Connecticut17:27 25-Oct-24
Genetic Engineering and Biotechnology News16:10 25-Oct-24
WUSF Public Media11:54 25-Oct-24
pharmaphorum07:34 25-Oct-24
WLRN07:06 25-Oct-24
JD Supra17:21 24-Oct-24
Oswaldo Cruz Foundation (Press Release)11:37 24-Oct-24
IFLScience10:38 24-Oct-24
Medpage Today09:49 24-Oct-24
Ars Technica09:44 24-Oct-24
News-Medical.Net08:11 24-Oct-24
Benzinga07:21 24-Oct-24
Institut Pasteur06:13 24-Oct-24
Clinical Trials Arena05:02 24-Oct-24
News-Medical.Net23:01 23-Oct-24
BioWorld15:33 23-Oct-24
view more headlines
8 Nov 16:03

About our mRNA news

Latest news on mRNA (messenger RNA), covering vaccines, therapeutics, research breakthroughs, clinical trials, and biotech companies like Moderna and BioNTech.

Messenger RNA, or mRNA, has revolutionized the fields of vaccine development and medical therapeutics. The technology gained global attention during the COVID-19 pandemic, with the rapid development and deployment of highly effective mRNA-based vaccines from Pfizer-BioNTech and Moderna. As of April 2024, billions of doses of these vaccines have been administered worldwide, significantly reducing the severity and mortality of COVID-19.

Beyond COVID-19, mRNA technology shows immense promise for treating various diseases, including cancer, genetic disorders, and infectious diseases. Ongoing clinical trials are investigating mRNA-based therapies for conditions such as HIV, influenza, and Zika virus. Additionally, researchers are exploring the potential of personalized mRNA cancer vaccines, which could revolutionize cancer treatment by targeting individual patients' unique tumor profiles.

The success of mRNA vaccines has sparked increased interest and investment in the biotech companies leading this innovation. Moderna and BioNTech have seen significant growth and partnerships with major pharmaceutical companies. The technology's versatility has also attracted the attention of philanthropic organizations, such as the Bill and Melinda Gates Foundation, which are funding research to address global health challenges.

The rapid development and success of mRNA vaccines during the COVID-19 pandemic built upon decades of foundational research. Scientists' understanding of mRNA's role in protein synthesis, combined with advancements in lipid nanoparticle delivery systems, paved the way for this breakthrough. The pandemic accelerated the translation of this research into life-saving interventions, demonstrating the importance of sustained investment in basic science.

As mRNA technology continues to advance, it is crucial to stay informed about the latest developments, clinical trial results, and regulatory approvals. Our Â鶹´«Ã½ feed on mRNA provides comprehensive, up-to-date coverage from trusted sources, ensuring you have access to the most relevant information on this groundbreaking field and its impact on global health.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.